Hematologist @pennmedicine|Interests in health outcomes research in hemostasis and thrombosis|APD Penn hem/onc|Tweets are my own.
Philadelphia, PA
Joined May 2019
- Tweets120
- Following250
- Followers276
- Likes785
Allyson Pishko, MD MSCE retweeted
Apixaban and rivaroxaban are the most frequently used oral anticoagulants for acute venous thromboembolism, but data on the difference in bleeding risk between the drugs are lacking. Research findings from the COBRRA trial are summarized in a new Quick Take video. nejm.org/do/10.1056/NEJMdo00…
Allyson Pishko, MD MSCE retweeted
New in @NEJM: The experimental monoclonal antibody ianalumab may provide extended relief for immune thrombocytopenia. Results from the Phase III VAYHIT2 study are “ushering in a new era of hope for ITP patients,” said Adam Cuker, MD. @PennMedCSO #ASH25 spr.ly/60127h2P2
Allyson Pishko, MD MSCE retweeted
Presented at #ASH25:
In the VAYHIT2 phase 3 trial, ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag, with a stable platelet response at 6 months in a higher percentage of patients with 9 mg/kg of ianalumab than with placebo. Full trial results: nej.md/49OeoGf
@ASH_hematology
ALT 67th ASH Annual Meeting Original Article | Dec. 9, 2025 | NEJM.org Ianalumab plus Eltrombopag in Immune Thrombocytopenia (VAYHIT2) Figure 2. Kaplan–Meier Estimates of the Primary End Point. The NEJM identity sits at the bottom.
Allyson Pishko, MD MSCE retweeted
Poster session 🤩
Dr Lukas Ronner one of our hematology oncology fellows presenting his work in AML and critical illness 👏🏼👏🏼👏🏼 Mutational status might be the key for this hyper inflammatory state
@PennCancer
@KatieLaiMD_MPH
Allyson Pishko, MD MSCE retweeted
Dr Wang from MSK and previous fellow at Penn presenting a very interesting analysis of differences in outcomes of Asian patients with AML
#ASHKudos #ASH25 @XinWangMD
Love this graphic from great BDUC talk for working up abnormal bleeding! 🩸 #ASH25
Allyson Pishko, MD MSCE retweeted
Three videos show echocardiography in a woman who presented with acute pain, swelling, and bruising on the upper portion of her left knee after using an electronic massage gun.
Read the full case details in the Clinical Problem-Solving article “A Fruitful Workup” by N. Jain et al., from @PennMedicine and the University of Pennsylvania: nej.md/3HHMwrP
Allyson Pishko, MD MSCE retweeted
When compared with the standard assays to assess #ADAMTS13 activity for suspected TTP, newer point-of-care rapid assays demonstrated higher diagnostic accuracy and concordance and lower rates of discrepancies: ow.ly/Eqwz50WktlM
#thrombosis #ClottingDisorders #classicalheme
Allyson Pishko, MD MSCE retweeted
Each day, SEPTA buses and other public transit help health care staff get to their jobs and patients reach care. Proposed service cuts and fare hikes put these essential trips at risk. Act now to protect affordable, reliable transit: spr.ly/60084b3cs.
Our review out today on immune TTP
Immune thrombotic thrombocytopenic purpura (iTTP) is an immune-mediated disorder characterized by thrombocytopenia and microangiopathic hemolytic anemia.
Learn more in this Review. ja.ma/3ZsypvR
Such awesome work @kellybeckphd !!
YourMomCares Organization Awards $100,000 to Project Aiding Neurodivergent Children in Schools people.com/your-mom-cares-or… via @people
Allyson Pishko, MD MSCE retweeted
How come nobody ever told me about Pittsburgh? It’s so nice here with the hills and the water and lots of sauerkraut for some reason. Big fan.
Allyson Pishko, MD MSCE retweeted
Patients with hereditary hemorrhagic telangiectasia (HHT) received pomalidomide or placebo for 24 weeks. Pomalidomide reduced epistaxis frequency and severity. Full PATH-HHT trial results: nej.md/3MUk9VW
ALT Graph of the estimated mean changes, from the mixed model for repeated measures, in the Epistaxis Severity Score.
Allyson Pishko, MD MSCE retweeted
Congratulations to Douglas Cines, MD (@PennPathLabMed) on being awarded the 2024 Henry M. Stratton Medal for basic science from @ASH_hematology for more than 40 years of research discoveries in thrombocytopenic disorders! #PennProud @DrNetto spr.ly/6017iTHu5
Allyson Pishko, MD MSCE retweeted
U.S. Unveils First 10 Drugs for Medicare Price Negotiations medpagetoday.com/washington-… As suspected both Eliquis and Xarelto made the list
Allyson Pishko, MD MSCE retweeted
Platelet counts often fall during pregnancy; decreases below 50X10^3 per cubic millimeter may be due to an autoimmune cause. Detection and management of immune thrombocytopenia may be lifesaving. Read more in “Management of Primary Immune Thrombocytopenia in Pregnancy”:
Allyson Pishko, MD MSCE retweeted
Confirmation that bone marrow analysis is not usually required in patients with cytopenias and advanced liver disease. Only 1/118 patients was found to have myelodysplasia to explain the cytopenia. tinyurl.com/3xm7rrzc
Allyson Pishko, MD MSCE retweeted
📣 Anticoag providers: Discussing HMB should be Standard of Care when treating pts that menstruate🩸
💡 Know the facts
✅ CHCs can be safely cont’d on AC
✅ Quality of life matters 🫶🏼
✅ TXA may have a role
✅ Apix & Dabi appear to have ⬇️ risk of HMB
@bsamuelson_md #ISTH2023
Excellent presentation by @HilaryWhitworth on 🩸🩸 definitions for pediatric VTE work. Love inclusion of “patient important bleeding”! #ISTH2023
